Atrion (NASDAQ:ATRI) Trading Up 5.6%

Atrion Co. (NASDAQ:ATRI) shares shot up 5.6% during mid-day trading on Friday . The company traded as high as $407.29 and last traded at $407.29. 27,813 shares were traded during mid-day trading, an increase of 63% from the average session volume of 17,037 shares. The stock had previously closed at $385.70.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Atrion from a “sell” rating to a “hold” rating in a report on Friday, March 1st.

Atrion Stock Performance

The stock’s fifty day moving average price is $401.11 and its 200-day moving average price is $364.89. The firm has a market cap of $708.14 million, a PE ratio of 36.48 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last posted its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The firm had revenue of $43.58 million during the quarter.

Atrion Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 15th were issued a dividend of $2.20 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $8.80 annualized dividend and a yield of 2.19%. Atrion’s dividend payout ratio (DPR) is currently 79.78%.

Hedge Funds Weigh In On Atrion

Several hedge funds have recently added to or reduced their stakes in ATRI. Kayne Anderson Rudnick Investment Management LLC increased its holdings in Atrion by 7.7% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 205,297 shares of the medical instruments supplier’s stock valued at $128,908,000 after acquiring an additional 14,684 shares in the last quarter. Penn Mutual Asset Management LLC purchased a new stake in shares of Atrion during the fourth quarter worth about $1,949,000. Citizens Financial Group Inc. RI purchased a new stake in shares of Atrion during the fourth quarter worth about $1,114,000. Barclays PLC grew its holdings in shares of Atrion by 356.3% during the fourth quarter. Barclays PLC now owns 2,336 shares of the medical instruments supplier’s stock worth $885,000 after buying an additional 1,824 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Atrion by 499.4% during the fourth quarter. Royal Bank of Canada now owns 2,056 shares of the medical instruments supplier’s stock worth $779,000 after buying an additional 1,713 shares in the last quarter. 66.19% of the stock is currently owned by hedge funds and other institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.